Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02456571 · ClinicalTrials.gov registry record
CTC Immune Checkpoint
A clinical trial, sponsored by Duke University.
- Completed
- Registry status
- 38
- Enrollment target
NCT02456571 is a clinical trial that has completed, run by Duke University. The registered enrollment target is 38 participants.
The verdict
NCT02456571 has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- 38 participants
- Enrollment target
Study Summary
This pilot study will explore the prevalence of expression of four immune checkpoint biomarkers on circulating tumor cells (CTCs) from men with metastatic prostate cancer that are captured by EpCAM via the CellSearch method, and specifically defined as co expressing DAPI and cytokeratin, and lacking CD45 expression.
Interventions
- DEVICE CTC biomarker expression prevalence
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2016-11 |
| Est. Completion | 2019-06-13 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02456571
The ClinicalTrials.gov registry entry for NCT02456571 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CTC biomarker expression prevalence is the first listed.
NCT02456571 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02456571 about?
NCT02456571 is a clinical study titled "CTC Immune Checkpoint". This pilot study will explore the prevalence of expression of four immune checkpoint biomarkers on circulating tumor cells (CTCs) from men with metastatic prostate cancer that are captured by EpCAM via the CellSearch method, and specifically defined as co expressing DAPI and cytokeratin, and lacking...
What is the current status of trial NCT02456571?
This trial is currently completed. The enrollment target is 38 participants. The study started on 2016-11. Estimated completion is 2019-06-13.
What interventions are being tested in trial NCT02456571?
The interventions under investigation include: CTC biomarker expression prevalence (DEVICE).
Who is sponsoring clinical trial NCT02456571?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.